vs
豪洛捷（HOLX）与Rivian Automotive, Inc.（RIVN）财务数据对比。点击上方公司名可切换其他公司
Rivian Automotive, Inc.的季度营收约是豪洛捷的1.2倍（$1.3B vs $1.0B），豪洛捷净利率更高（17.1% vs -63.1%，领先80.2%），豪洛捷同比增速更快（2.5% vs -25.8%），豪洛捷自由现金流更多（$215.2M vs $-1.1B），过去两年Rivian Automotive, Inc.的营收复合增速更高（3.3% vs 1.5%）
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
Rivian Automotive是2009年成立的美国电动汽车制造商及汽车科技企业，主打基于自研滑板平台打造的电动SUV、皮卡及EDV电动配送货车，旗下R1T皮卡于2021年末正式开启交付，还计划于2023年底前在美国和加拿大布局专属充电网络，其平台可适配新车型也可对外授权使用。
HOLX vs RIVN — 直观对比
营收规模更大
RIVN
是对方的1.2倍
$1.0B
营收增速更快
HOLX
高出28.4%
-25.8%
净利率更高
HOLX
高出80.2%
-63.1%
自由现金流更多
HOLX
多$1.4B
$-1.1B
两年增速更快
RIVN
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $1.3B |
| 净利润 | $179.1M | $-811.0M |
| 毛利率 | 56.0% | 9.3% |
| 营业利润率 | 22.6% | -64.8% |
| 净利率 | 17.1% | -63.1% |
| 营收同比 | 2.5% | -25.8% |
| 净利润同比 | -10.9% | -9.0% |
| 每股收益（稀释后） | $0.79 | $-0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOLXRIVN
| Q4 25 | $1.0B | $1.3B | ||
| Q3 25 | $1.0B | $1.6B | ||
| Q2 25 | $1.0B | $1.3B | ||
| Q1 25 | $1.0B | $1.2B | ||
| Q4 24 | $1.0B | $1.7B | ||
| Q3 24 | $988.0M | $874.0M | ||
| Q2 24 | $1.0B | $1.2B | ||
| Q1 24 | $1.0B | $1.2B |
净利润HOLXRIVN
| Q4 25 | $179.1M | $-811.0M | ||
| Q3 25 | $187.2M | $-1.2B | ||
| Q2 25 | $194.9M | $-1.1B | ||
| Q1 25 | $-17.4M | $-545.0M | ||
| Q4 24 | $201.0M | $-744.0M | ||
| Q3 24 | $178.6M | $-1.1B | ||
| Q2 24 | $194.5M | $-1.5B | ||
| Q1 24 | $169.9M | $-1.4B |
毛利率HOLXRIVN
| Q4 25 | 56.0% | 9.3% | ||
| Q3 25 | 55.6% | 1.5% | ||
| Q2 25 | 56.3% | -15.8% | ||
| Q1 25 | 37.5% | 16.6% | ||
| Q4 24 | 56.8% | 9.8% | ||
| Q3 24 | 56.4% | -44.9% | ||
| Q2 24 | 55.4% | -38.9% | ||
| Q1 24 | 53.3% | -43.8% |
营业利润率HOLXRIVN
| Q4 25 | 22.6% | -64.8% | ||
| Q3 25 | 22.6% | -63.1% | ||
| Q2 25 | 24.9% | -85.5% | ||
| Q1 25 | -0.7% | -52.8% | ||
| Q4 24 | 22.5% | -38.1% | ||
| Q3 24 | 23.3% | -133.8% | ||
| Q2 24 | 24.1% | -118.7% | ||
| Q1 24 | 20.7% | -123.3% |
净利率HOLXRIVN
| Q4 25 | 17.1% | -63.1% | ||
| Q3 25 | 17.8% | -75.3% | ||
| Q2 25 | 19.0% | -85.7% | ||
| Q1 25 | -1.7% | -44.0% | ||
| Q4 24 | 19.7% | -42.9% | ||
| Q3 24 | 18.1% | -125.9% | ||
| Q2 24 | 19.2% | -125.8% | ||
| Q1 24 | 16.7% | -120.1% |
每股收益（稀释后）HOLXRIVN
| Q4 25 | $0.79 | $-0.66 | ||
| Q3 25 | $0.84 | $-0.96 | ||
| Q2 25 | $0.86 | $-0.97 | ||
| Q1 25 | $-0.08 | $-0.48 | ||
| Q4 24 | $0.87 | $-0.67 | ||
| Q3 24 | $0.75 | $-1.08 | ||
| Q2 24 | $0.82 | $-1.46 | ||
| Q1 24 | $0.72 | $-1.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $6.1B |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $5.2B | $4.6B |
| 总资产 | $9.2B | $14.9B |
| 负债/权益比越低杠杆越低 | 0.48× | — |
8季度趋势，按日历期对齐
现金及短期投资HOLXRIVN
| Q4 25 | $2.4B | $6.1B | ||
| Q3 25 | $2.2B | $7.1B | ||
| Q2 25 | $1.9B | $7.5B | ||
| Q1 25 | $1.6B | $7.2B | ||
| Q4 24 | $2.0B | $7.7B | ||
| Q3 24 | $2.3B | $6.7B | ||
| Q2 24 | $2.4B | $7.9B | ||
| Q1 24 | $2.2B | $7.9B |
总债务HOLXRIVN
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | $5.5B | ||
| Q1 24 | $2.6B | $4.4B |
股东权益HOLXRIVN
| Q4 25 | $5.2B | $4.6B | ||
| Q3 25 | $5.0B | $5.1B | ||
| Q2 25 | $4.8B | $6.1B | ||
| Q1 25 | $4.6B | $6.2B | ||
| Q4 24 | $4.8B | $6.6B | ||
| Q3 24 | $5.1B | $5.9B | ||
| Q2 24 | $5.0B | $6.8B | ||
| Q1 24 | $4.8B | $8.1B |
总资产HOLXRIVN
| Q4 25 | $9.2B | $14.9B | ||
| Q3 25 | $9.0B | $15.2B | ||
| Q2 25 | $8.8B | $15.6B | ||
| Q1 25 | $8.5B | $15.5B | ||
| Q4 24 | $8.7B | $15.4B | ||
| Q3 24 | $9.2B | $14.3B | ||
| Q2 24 | $8.9B | $15.4B | ||
| Q1 24 | $8.7B | $15.7B |
负债/权益比HOLXRIVN
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | 0.81× | ||
| Q1 24 | 0.53× | 0.55× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.9M | $-681.0M |
| 自由现金流经营现金流 - 资本支出 | $215.2M | $-1.1B |
| 自由现金流率自由现金流/营收 | 20.5% | -89.0% |
| 资本支出强度资本支出/营收 | 1.4% | 36.0% |
| 现金转化率经营现金流/净利润 | 1.28× | — |
| 过去12个月自由现金流最近4个季度 | $1.0B | $-2.5B |
8季度趋势，按日历期对齐
经营现金流HOLXRIVN
| Q4 25 | $229.9M | $-681.0M | ||
| Q3 25 | $355.1M | $26.0M | ||
| Q2 25 | $343.3M | $64.0M | ||
| Q1 25 | $169.4M | $-188.0M | ||
| Q4 24 | $189.3M | $1.2B | ||
| Q3 24 | $367.0M | $-876.0M | ||
| Q2 24 | $405.8M | $-754.0M | ||
| Q1 24 | $292.4M | $-1.3B |
自由现金流HOLXRIVN
| Q4 25 | $215.2M | $-1.1B | ||
| Q3 25 | $341.4M | $-421.0M | ||
| Q2 25 | $330.5M | $-398.0M | ||
| Q1 25 | $153.9M | $-526.0M | ||
| Q4 24 | $172.5M | $856.0M | ||
| Q3 24 | $350.6M | $-1.2B | ||
| Q2 24 | $385.3M | $-1.0B | ||
| Q1 24 | $279.6M | $-1.5B |
自由现金流率HOLXRIVN
| Q4 25 | 20.5% | -89.0% | ||
| Q3 25 | 32.5% | -27.0% | ||
| Q2 25 | 32.3% | -30.5% | ||
| Q1 25 | 15.3% | -42.4% | ||
| Q4 24 | 16.9% | 49.4% | ||
| Q3 24 | 35.5% | -131.9% | ||
| Q2 24 | 38.1% | -89.6% | ||
| Q1 24 | 27.5% | -126.5% |
资本支出强度HOLXRIVN
| Q4 25 | 1.4% | 36.0% | ||
| Q3 25 | 1.3% | 28.7% | ||
| Q2 25 | 1.3% | 35.5% | ||
| Q1 25 | 1.5% | 27.3% | ||
| Q4 24 | 1.6% | 18.9% | ||
| Q3 24 | 1.7% | 31.7% | ||
| Q2 24 | 2.0% | 24.4% | ||
| Q1 24 | 1.3% | 21.1% |
现金转化率HOLXRIVN
| Q4 25 | 1.28× | — | ||
| Q3 25 | 1.90× | — | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | — | ||
| Q2 24 | 2.09× | — | ||
| Q1 24 | 1.72× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
RIVN
| Automotive Segment | $839.0M | 65% |
| Software And Services Segment | $447.0M | 35% |
| Regulatory Credits | $30.0M | 2% |
